Compare Stocks: TVGN, LUCD, NGEN, and KRRO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KRRO Korro Bio	$12.93 -4.3%	$12.64	$5.20 ▼ $55.89	$198.94M	3.09	73,594 shs	131,500 shs
LUCD Lucid Diagnostics	$0.82 -8.4%	$0.97	$0.81 ▼ $1.63	$182.27M	1.1	784,145 shs	1.77 million shs
NGEN NervGen Pharma	$2.13 -2.7%	$1.88	$1.58 ▼ $6.30	$176.58M	N/A	615,965 shs	365,094 shs
TVGN Tevogen Bio	$7.34 +0.1%	$6.11	$3.64 ▼ $44.88	$47.73M	0.17	5,257 shs	4,079 shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KRRO Korro Bio	-4.29%	+8.02%	-4.15%	+22.79%	-64.20%
LUCD Lucid Diagnostics	-8.44%	-17.05%	-14.57%	-16.05%	-35.35%
NGEN NervGen Pharma	-2.74%	-8.58%	+25.29%	+12.70%	+212,999,900.00%
TVGN Tevogen Bio	+0.14%	+2.37%	+14.87%	-37.10%	-83.41%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KRRO Korro Bio	$12.93 -4.3%	$12.64	$5.20 ▼ $55.89	$198.94M	3.09	73,594 shs	131,500 shs
LUCD Lucid Diagnostics	$0.82 -8.4%	$0.97	$0.81 ▼ $1.63	$182.27M	1.1	784,145 shs	1.77 million shs
NGEN NervGen Pharma	$2.13 -2.7%	$1.88	$1.58 ▼ $6.30	$176.58M	N/A	615,965 shs	365,094 shs
TVGN Tevogen Bio	$7.34 +0.1%	$6.11	$3.64 ▼ $44.88	$47.73M	0.17	5,257 shs	4,079 shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KRRO Korro Bio	-4.29%	+8.02%	-4.15%	+22.79%	-64.20%
LUCD Lucid Diagnostics	-8.44%	-17.05%	-14.57%	-16.05%	-35.35%
NGEN NervGen Pharma	-2.74%	-8.58%	+25.29%	+12.70%	+212,999,900.00%
TVGN Tevogen Bio	+0.14%	+2.37%	+14.87%	-37.10%	-83.41%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
KRRO Korro Bio	2.92	Moderate Buy	$16.71	29.27% Upside
LUCD Lucid Diagnostics	2.60	Moderate Buy	$4.19	409.99% Upside
NGEN NervGen Pharma	2.83	Moderate Buy	$14.00	557.28% Upside
TVGN Tevogen Bio	1.50	Reduce	$100.00	1,262.40% Upside

Current Analyst Ratings Breakdown

Latest TVGN, LUCD, NGEN, and KRRO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/20/2026	KRRO Korro Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$15.00
8/18/2026	LUCD Lucid Diagnostics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/17/2026	LUCD Lucid Diagnostics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$2.50
8/4/2026	LUCD Lucid Diagnostics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/4/2026	NGEN NervGen Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/21/2026	NGEN NervGen Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/20/2026	LUCD Lucid Diagnostics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/17/2026	TVGN Tevogen Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/13/2026	NGEN NervGen Pharma	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$10.00
7/6/2026	KRRO Korro Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/11/2026	NGEN NervGen Pharma	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy

(Data available from 9/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
KRRO Korro Bio	$6.39M	29.81	N/A	N/A	$5.46 per share	2.37
LUCD Lucid Diagnostics	$4.71M	35.43	N/A	N/A	($0.31) per share	-2.65
NGEN NervGen Pharma	N/A	N/A	N/A	N/A	$0.03 per share	N/A
TVGN Tevogen Bio	N/A	N/A	N/A	N/A	($211.84) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
KRRO Korro Bio	-$117.26M	-$10.00	N/A	N/A	N/A	-1,834.48%	-114.26%	-68.57%	11/11/2026 (Estimated)
LUCD Lucid Diagnostics	-$58.01M	-$0.47	N/A	N/A	N/A	-959.76%	N/A	-119.57%	11/11/2026 (Estimated)
NGEN NervGen Pharma	-$31.58M	-$0.46	N/A	N/A	N/A	N/A	-1,259.82%	-199.79%	N/A
TVGN Tevogen Bio	-$26.27M	-$4.63	N/A	N/A	N/A	N/A	N/A	-468.32%	11/13/2026 (Estimated)

Latest TVGN, LUCD, NGEN, and KRRO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	TVGN Tevogen Bio	-$2.53	-$1.52	+$1.01	-$1.52	N/A	N/A
8/13/2026	Q2 2026	LUCD Lucid Diagnostics	-$0.0567	-$0.06	-$0.0033	-$0.08	$1.43 million	$1.47 million
8/13/2026	Q2 2026	NGEN NervGen Pharma	-$0.09	-$0.37	-$0.28	-$0.37	N/A	N/A
8/6/2026	Q2 2026	KRRO Korro Bio	-$1.34	-$1.07	+$0.27	-$1.07	$0.21 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
KRRO Korro Bio	N/A	N/A	N/A	N/A	N/A
LUCD Lucid Diagnostics	N/A	N/A	N/A	N/A	N/A
NGEN NervGen Pharma	N/A	N/A	N/A	N/A	N/A
TVGN Tevogen Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
KRRO Korro Bio	N/A	9.55	9.55
LUCD Lucid Diagnostics	N/A	1.33	1.31
NGEN NervGen Pharma	N/A	1.23	1.23
TVGN Tevogen Bio	N/A	0.33	0.33

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
KRRO Korro Bio	13.18%
LUCD Lucid Diagnostics	74.01%
NGEN NervGen Pharma	N/A
TVGN Tevogen Bio	N/A

Insider Ownership

Company	Insider Ownership
KRRO Korro Bio	4.80%
LUCD Lucid Diagnostics	6.90%
NGEN NervGen Pharma	5.80%
TVGN Tevogen Bio	65.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
KRRO Korro Bio	70	14.73 million	14.02 million	No Data
LUCD Lucid Diagnostics	70	203.24 million	189.22 million	No Data
NGEN NervGen Pharma	N/A	80.63 million	75.95 million	N/A
TVGN Tevogen Bio	3	6.51 million	2.24 million	N/A

TVGN, LUCD, NGEN, and KRRO Headlines

Recent News About These Companies

Tevogen Bio Holdings Rebrands as Tevogen Inc.

July 30, 2026 | tipranks.com

Tevogen Bio Holdings Corporate Event Calendar | NASDAQ:TVGN

July 24, 2026 | benzinga.com

Tevogen Bio Announces 2026 Annual Meeting of Stockholders

July 13, 2026 | globenewswire.com

Tevogen Bio Inc: Tevogen Announces Formation of a Healthcare Services Initiative

June 10, 2026 | finanznachrichten.de

Tevogen Bio Holdings Inc. Announces William Keane as Interim Head of New Healthcare Services Initiative, Exploring MSO and CRO Acquisitions

June 9, 2026 | quiverquant.comQ

Tevogen Announces Formation of a Healthcare Services Initiative

June 9, 2026 | globenewswire.com

Tevogen Bio Inc: Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 Million in Combined Annual Revenue

May 28, 2026 | finanznachrichten.de

Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 ...

May 28, 2026 | enidnews.comE

Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 Million in Combined Annual Revenue

May 28, 2026 | globenewswire.com

Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Management Services ...

May 21, 2026 | caledonianrecord.comC

Tevogen Bio Holdings Inc. Signs Non-Binding Letter of Intent to Explore Strategic Healthcare Transaction

May 21, 2026 | quiverquant.comQ

Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Management Services Organization

May 21, 2026 | globenewswire.com

Tevogen Bio Holdings Inc. Reports Significant Operational Improvements and Strategic Growth Initiatives

May 18, 2026 | quiverquant.comQ

Letter to Shareholders from CEO Dr. Ryan Saadi

May 18, 2026 | globenewswire.com

Tevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest ...

May 12, 2026 | caledonianrecord.comC

Tevogen Bio Holdings Inc. Secures $3 Million PIPE Financing from The Patel Family, LLP

May 12, 2026 | quiverquant.comQ

Tevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest Market Close

May 12, 2026 | globenewswire.com

Tevogen (TVGN) Soars 11% as Firm Gears Up for AI Training Commercialization

May 5, 2026 | finance.yahoo.com

Tevogen.AI Nears Completion of PredicTcell™ Training; Initiates Commercial Readiness and Debuts Internal Application Portal

April 27, 2026 | finance.yahoo.com

Tevogen.AI Nears Completion of PredicTcellâ„¢ Training; Initiates Commercial Readiness and Debuts Internal Application Portal

April 27, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TVGN, LUCD, NGEN, and KRRO Company Descriptions

Korro Bio NASDAQ:KRRO

$12.93 -0.58 (-4.29%)

Closing price 09/9/2026 04:00 PM Eastern

Extended Trading

$12.92 -0.01 (-0.08%)

As of 09/9/2026 07:30 PM Eastern

Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Lucid Diagnostics NASDAQ:LUCD

$0.82 -0.08 (-8.44%)

Closing price 09/9/2026 04:00 PM Eastern

Extended Trading

$0.84 +0.02 (+1.94%)

As of 09/9/2026 07:59 PM Eastern

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

NervGen Pharma NASDAQ:NGEN

$2.13 -0.06 (-2.74%)

Closing price 09/9/2026 04:00 PM Eastern

Extended Trading

$2.14 +0.01 (+0.47%)

As of 09/9/2026 07:30 PM Eastern

NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. The company was incorporated in 2017 and is based in Vancouver, Canada.

Tevogen Bio NASDAQ:TVGN

$7.34 +0.01 (+0.14%)

Closing price 09/9/2026 04:00 PM Eastern

Extended Trading

$7.28 -0.06 (-0.82%)

As of 09/9/2026 07:30 PM Eastern

Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TVGN, LUCD, NGEN, and KRRO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TVGN, LUCD, NGEN, and KRRO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TVGN, LUCD, NGEN, and KRRO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TVGN, LUCD, NGEN, and KRRO Company Descriptions

Korro Bio NASDAQ:KRRO

Lucid Diagnostics NASDAQ:LUCD

NervGen Pharma NASDAQ:NGEN

Tevogen Bio NASDAQ:TVGN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TVGN, LUCD, NGEN, and KRRO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TVGN, LUCD, NGEN, and KRRO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TVGN, LUCD, NGEN, and KRRO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TVGN, LUCD, NGEN, and KRRO Company Descriptions

Korro Bio NASDAQ:KRRO

Lucid Diagnostics NASDAQ:LUCD

NervGen Pharma NASDAQ:NGEN

Tevogen Bio NASDAQ:TVGN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools